Skip to main content

Copernicus Capital Management, LLC

SEC CIK
0001694620
Latest filing
Nov 15, 2021

The latest 13F from Copernicus Capital Management, LLC covers Q3 2021 (filed Nov 15, 2021): 13 long positions worth $8.26M. The top 10 holdings make up 93.2% of the portfolio, and the largest is Pfizer Inc (PFE) at 15.6%. Livermore has 3 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2021

Share counts compared with Q2 2021: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
10
Est. +$6.30M
Added
2
Est. +$228.0K
Reduced
1
Est. −$104.6K
Sold out
8
Est. −$4.84M

Top 5 holdings

Share of this quarter's portfolio value

  1. PFEPfizer Inc
    15.6%$1.29MHistory
  2. TMOThermo Fisher Scientific Inc.
    13.8%$1.14MHistory
  3. TDOCTeladoc Health, Inc.
    10.7%$888.0KHistory
  4. BMRNBiomarin Pharmaceutical Inc
    10.3%$850.0KHistory
  5. JNJJohnson & Johnson
    9.8%$808.0KHistory

Biggest buys

New and added positions, by estimated amount bought

  1. PFEPfizer Inc
    +$1.29MNewHistory
  2. TMOThermo Fisher Scientific Inc.
    +$1.14MNewHistory
  3. TDOCTeladoc Health, Inc.
    +$888.0KNewHistory
  4. BMRNBiomarin Pharmaceutical Inc
    +$850.0KNewHistory
  5. JNJJohnson & Johnson
    +$808.0KNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. PFEPfizer Inc
    +15.61 pp0.0% → 15.6%History
  2. TMOThermo Fisher Scientific Inc.
    +13.83 pp0.0% → 13.8%History
  3. TDOCTeladoc Health, Inc.
    +10.75 pp0.0% → 10.7%History
  4. BMRNBiomarin Pharmaceutical Inc
    +10.29 pp0.0% → 10.3%History
  5. JNJJohnson & Johnson
    +9.78 pp0.0% → 9.8%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. VRTXVertex Pharmaceuticals Inc
    −$1.81MSold outHistory
  2. ATRAAtara Biotherapeutics, Inc.
    −$778.0KSold outHistory
  3. ZNTLZentalis Pharmaceuticals, Inc.
    −$532.0KSold outHistory
  4. TCRRTCR2 Therapeutics Inc.
    −$492.0KSold outHistory
  5. ACCDAccolade, Inc.
    −$380.0KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. VRTXVertex Pharmaceuticals Inc
    −28.62 pp28.6% → 0.0%History
  2. ATRAAtara Biotherapeutics, Inc.
    −12.27 pp12.3% → 0.0%History
  3. ZNTLZentalis Pharmaceuticals, Inc.
    −8.39 pp8.4% → 0.0%History
  4. TCRRTCR2 Therapeutics Inc.
    −7.76 pp7.8% → 0.0%History
  5. ACCDAccolade, Inc.
    −5.99 pp6.0% → 0.0%History

Metrics

13F metrics for Q3 2021, computed only from the numbers in the filings. Definitions below.

Portfolio value
$8.26M
+$1.92M (+30.3%) vs. prior quarter
Positions
13
+2 vs. prior quarter
Top 10 concentration
93.2%
Top 10 as share of value
Turnover
67.7%
Q3 2021, one quarter
Average holding period
1.4 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

3 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $8.26M (Q3 2021)

Q1 2021: $6.19MQ2 2021: $6.34MQ3 2021: $8.26M
Q1 2021Q3 2021
13F filings of Copernicus Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2021Nov 15, 202113$8.26MPFETMOTDOCvs. Q2 2021SEC
Q2 2021Aug 16, 202111$6.34MVRTXFATEATRAvs. Q1 2021SEC
Q1 2021May 17, 202114$6.19MBMRNREGNFATE–SEC